Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Transcode Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −7 vs. Q4 2022
- Shares held
- 262.2K
- −83.0K (−24.0%) vs. Q4 2022
- Total value
- $88.6K
- −$133.9K (−60.2%) vs. Q4 2022
- New holders
- 2
- 2 more added
- Sold out
- 9
- 3 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RNAZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $208.1K |
| Q1 2026 | 8 | $265.7K |
| Q4 2025 | 6 | $26.4K |
| Q3 2025 | 8 | $155.0K |
| Q2 2025 | 9 | $237.0K |
| Q1 2025 | 19 | $1.06M |
| Q4 2024 | 5 | $33.4K |
| Q3 2024 | 10 | $185.8K |
| Q2 2024 | 15 | $263.0K |
| Q1 2024 | 7 | $284.1K |
| Q4 2023 | 13 | $105.4K |
| Q3 2023 | 11 | $281.6K |
| Q2 2023 | 5 | $476.6K |
| Q1 2023 | 11 | $88.6K |
| Q4 2022 | 18 | $222.5K |
| Q3 2022 | 13 | $2.27M |
| Q2 2022 | 13 | $2.67M |
| Q1 2022 | 13 | $3.14M |
| Q4 2021 | 16 | $5.98M |
| Q3 2021 | 17 | $7.28M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Transcode Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 75,683 | $25.6K | 0.00% | −866−1.1% | Reduced |
| Sheets Smith Wealth Management | 60,000 | $20.3K | 0.00% | +35,000+140.0% | Added |
| One68 Global Capital, LLC | 30,120 | $10.2K | 0.01% | +30,120 | New |
| State Street Corp | 21,019 | $7.12K | 0.00% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 20,000 | $6.77K | 0.00% | +20,000 | New |
| Two Sigma Investments, LP | 19,407 | $6.57K | 0.00% | 00.0% | Unchanged |
| Shay Capital LLC | 15,060 | $5.10K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 13,122 | $4.44K | 0.00% | −4,000−23.4% | Reduced |
| Tower Research Capital LLC (TRC) | 6,351 | $2.00K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 1,385 | $469 | 0.00% | −14,293−91.2% | Reduced |
| Wells Fargo & Company | 51 | $17 | 0.00% | +1+2.0% | Added |
| Cahill Wealth Management, LLC | 0 | $0 | 0.00% | −47,060−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −25,995−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −20,854−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −16,361−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −13,500−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −12,880−100.0% | Sold out |
| Triumph Capital Management | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −1,165−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,159−100.0% | Sold out |